Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Nexstim

7.84

 

EUR

 

-1.26 %

5,436 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Investor consensus
-1.26%
-6%
-14.97%
-0.76%
+60%
+254.75%
+47.37%
+749.68%
-98.71%

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
56.32M EUR
Turnover
9.24K EUR
P/E (adj.) (25e)
16.38
EV/EBIT (adj.) (25e)
17.53
P/B (25e)
10.41
EV/S (25e)
3.8
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
9.00 EUR
Updated
04.03.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 04.03.2025

Latest extensive report

Released: 06.10.2023

Revenue and EBIT-%
21.721.714.414.47.27.2008.8-16.9-6.121.723.129.322222323242425e25e26e26e27e27e

Revenue M

EBIT-% (adj.)

EPS and dividend
0.90.90.50.50.20.2-0.2-0.222222323242425e25e26e26e27e27e

EPS (adj.)

Dividend %

Financial calendar
15.8
2025

Interim report Q2'25

Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types
Regulatory press release4/16/2025, 9:30 AM

Nexstim Plc: Managers’ Transactions, Forss

Nexstim
Regulatory press release4/11/2025, 1:50 PM

Nexstim Plc: Share subscriptions based on stock options 2018 and 2020

Nexstim
Press release3/28/2025, 7:00 AM

Nexstim Receives System Order from US University

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/27/2025, 9:45 AM

Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders

Nexstim
Regulatory press release3/6/2025, 10:30 AM

Nexstim Plc: Managers’ Transactions, Karvinen

Nexstim
Regulatory press release3/6/2025, 8:00 AM

Nexstim Plc: Invitation to the Annual General Meeting

Nexstim
Regulatory press release3/6/2025, 7:30 AM

Nexstim Plc Publishes 2024 Annual Report

Nexstim
Nexstim: Returning to the buy side after a share price decline
Research3/4/2025, 7:30 AM by
Antti Siltanen

Nexstim: Returning to the buy side after a share price decline

Nexstim's share price has fallen sharply in recent days, and the risk/reward ratio has become attractive again

Nexstim
Regulatory press release3/3/2025, 12:15 PM

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim
Regulatory press release3/3/2025, 12:00 PM

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim
Nexstim H2'24: Solid growth in line with expectations
Research2/28/2025, 8:13 AM by
Antti Siltanen

Nexstim H2'24: Solid growth in line with expectations

Nexstim's H2'24 was in line with our expectations, with revenue up 17%.

Nexstim
Regulatory press release2/27/2025, 7:00 AM

NEXSTIM PLC’S FINANCIAL STATEMENTS BULLETIN 2024

Nexstim
Nexstim H2'24 preview: Profitable H2 in expectations
Analyst Comment2/25/2025, 6:54 AM by
Antti Siltanen

Nexstim H2'24 preview: Profitable H2 in expectations

Nexstim will publish its H2 report on Thursday, February 27 at 9 am EET. The second half of an eventful year full of surprises was marked in particular by the cooperation agreement with Brainlab and the import license for the Indian market.

Nexstim
Press release2/24/2025, 1:00 PM

Notice of Nexstim Plc’s 2024 Full Year Results

Nexstim
Regulatory press release2/18/2025, 7:00 AM

Nexstim Plc: Proposals of the Shareholder’s Nomination Board to the Annual General Meeting

Nexstim
Press release2/17/2025, 8:00 AM

Distributor Orders Nexstim NBS System 5 for European Hospital

Nexstim
Regulatory press release1/15/2025, 7:00 AM

Insider Information: Nexstim Plc and Sinaptica Therapeutics, Inc. Announce Initiation of Co-Development of the SinaptiStim® Precision Neuromodulation System to treat Alzheimer’s Disease

Nexstim
Press release1/9/2025, 7:00 AM

Nexstim Receives NBS 5 System Order from New Customer in Ohio, United States

Nexstim
Research1/3/2025, 7:58 AM by
Antti Siltanen

Nexstim: Good end to a strong year

Nexstim's strong 2024 culminated in a seasonally busy Q4 sales season. The total number of system sales reported for the year was 28, up from 24 last year and the best sales year in Nexstim's history.

Nexstim
Press release1/2/2025, 7:00 AM

Nexstim Plc: Henri Hannula appointed as CCO

Nexstim
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.